Khona Scientific will utilize biomanufacturing technology to create bioidentical steroid hormones that align with EVEXIAS’ top-tier hormone therapy approaches.
BOULDER, CO, UNITED STATES, July 30, 2026 /EINPresswire.com/ — Khona Scientific, a trailblazer in biomanufacturing for intricate natural product compounds, is pleased to confirm the signing of a Letter of Intent (LOI) with EVEXIAS, a leading provider of hormone replacement and optimization therapies. Via careful planning and thorough validation, the two companies aim to create the steroid hormone supply chain of the future, right now.
Steroid hormones rank among the body’s most powerful chemical signals. They affect nearly every organ system and physiological function, playing key roles in metabolism, aging, immunity, reproduction, bone health, cardiovascular function, and cognition. Consequently, low steroid hormone levels produce widespread health effects that can be addressed through customized hormone therapies like those provided by EVEXIAS.
Just as low steroid hormone levels harm patients, supply chain weaknesses for these hormones can adversely affect treatment providers such as EVEXIAS. These supply challenges can be solved by advances in manufacturing. Currently, these compounds are obtained almost entirely from India and China. Khona Scientific’s move into steroid hormones stems from a goal to offer partners like EVEXIAS additional options for API sourcing to satisfy rising patient and physician demand. Building resilience via redundancy is the core aim of the partnership between Khona Scientific and EVEXIAS.
The initiative focuses on applying Khona Scientific’s BiDS™ technology to generate bioidentical steroid hormones for incorporation into EVEXIAS’ hormone therapy products after thorough validation. BiDS™ is a modular, flexible platform that manufactures complex active pharmaceutical ingredients (APIs) using plentiful, low-cost, renewable sugars as raw materials. The system functions like a ‘molecular assembly line’ – boosting yield, quality, throughput, and efficiency by arranging enzymes from multiple pathways in the optimal order inside a host cell to make the target compound. This setup maximizes output and removes bottlenecks found in older systems. Consequently, it allows scalable, affordable, on-demand API production that does not depend on specialized inputs. By separating steroid hormone API manufacturing from agricultural supply chains, Khona Scientific’s BiDS™ technology can assist EVEXIAS in maintaining continuous and consistent care for patients undergoing its personalized hormone therapy.
“Our mission has always been to deliver safe, effective, and reliable treatment options to patients and physicians,” stated Dan DeNeui, CEO of EVEXIAS. “We are eager to examine how Khona Scientific can support this mission through supply chain diversification for our hormone therapy products.”
Paul Orlady, CEO of Khona Scientific, stated: “We are excited to demonstrate Khona Scientific’s technology by providing a custom-built production pipeline that will strengthen the supply chain for EVEXIAS’ top-tier hormone therapy division. This marks a significant initial move toward our shared goal of improving health outcomes for patients seeking treatment for various conditions.”
The LOI covers several steroid hormones, specifically progesterone, estradiol, estrone, and estriol. Estradiol is a standard treatment for menopause symptoms like hot flashes and night sweats, as well as for preventing bone loss (osteoporosis). Progesterone is often used alongside estradiol in hormone therapy to address menopausal symptoms and provide endometrial protection. Estradiol and progesterone are also used in non-menopausal contexts such as infertility treatment, managing polycystic ovarian syndrome (PCOS), and in assisted reproductive technologies.
